BioArts International has been granted a sole, worldwide license for the cloning of dogs, cats and endangered species by Start Licensing, which controls these rights. Start Licensing’s patents include foundational nuclear transfer cloning technology developed at the Roslin Institute for the cloning of Dolly the sheep. By obtaining a license to certain aspects of these patents, BioArts will be able to employ a suite of sophisticated biotechnology tools to produce healthy cloned animals. While other companies might claim companion animal cloning capabilities, BioArts is the only entity in the world with both the know-how and the legal right to practice commercial dog (and cat) cloning.

About Start Licensing

Start is a joint venture of Geron Corporation and Exeter Life Sciences. Start manages and licenses a broad portfolio of intellectual property rights related to animal reproductive technologies, including foundational nuclear transfer cloning technology developed at the Roslin Institute for the cloning of Dolly the sheep. Start's licensees are on the cutting edge of research and product development in food production, medical applications and many other fields.